Imatinib plus granulocyte colony-stimulating factor in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response while on imatinib

Case Reports in Oncology

Volumn 4, Issue 1, 2011, Pages 192-197

  Fang, Baijun ^a,b   Mai, Ling ^a   Li, Ning ^a   Song, Yongping ^a   Zhao, Robert Chunhua ^b  

^a ZHENGZHOU UNIVERSITY   (China)

^b PEKING UNION MEDICAL COLLEGE   (China)

Author keywords

Chronic myeloid leukemia; Granulocyte colony stimulating factor; Imatinib

Indexed keywords

BCR ABL PROTEIN; GRANULOCYTE COLONY STIMULATING FACTOR; IMATINIB;

ADULT; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CYTOGENETICS; DRUG WITHDRAWAL; FATIGUE; FEMALE; HUMAN; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MYALGIA; NAUSEA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; REVIEW; TREATMENT DURATION; TREATMENT RESPONSE;

EID: 79957604956     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000327512     Document Type: Review

References (23)

1. Rowley JD: A new consistent chromosome abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973;243:209-213.
2. de Klein A, van Kessel AG, Grosveld G, Bartram CR, Hagemeijer A, Bootsma D, Spurr NK, Heisterkamp N, Groffen J, Stephenson JR: A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia. Nature 1982;300:765-767. (Pubitemid 13224358)
3. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ; IRIS Investigators: Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994-1004. (Pubitemid 36302244)
4. Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP; International Randomised Study of Interferon versus STI571 (IRIS) Study Group: Frequency of major molecular responses to imatinib or interferon α plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med 2003;349:1423-1432. (Pubitemid 37211057)
5. Bhatia R, Holtz M, Niu N, Gray R, Snyder DS, Sawyers CL, Arber DA, Slovak ML, Forman SJ: Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment. Blood 2003;101:4701-4707. (Pubitemid 36857723)
6. Gorre ME, Mohammed M, Ellwood K, Hsu N, Paquette R, Rao PN, Sawyers CL: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-880. (Pubitemid 32743979)
7. Holyoake T, Jiang X, Eaves C, Eaves A: Isolation of a highly quiescent subpopulation of primitive leukemic cells in chronic myeloid leukemia. Blood 1999;94:2056-2064. (Pubitemid 29430422)
8. Graham SM, Jorgensen HG, Allan E, Pearson C, Alcorn MJ, Richmond L, Holyoake TL: Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood 2002;99:319-325.
9. Holtz MS, Slovak ML, Zhang F, Sawyers CL, Forman SJ, Bhatia R: Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation. Blood 2002;99:3792-3800. (Pubitemid 34534553)
10. Jorgensen HG, Copland M, Allan EK, Jiang X, Eaves A, Eaves C, Holyoake TL: Intermittent exposure of primitive quiescent chronic myeloid leukemia cells to granulocyte-colony stimulating factor in vitro promotes their elimination by imatinib mesylate. Clin Cancer Res 2006;12:626-633. (Pubitemid 43166158)
11. Holtz M, Forman SJ, Bhatia R: Growth factor stimulation reduces residual quiescent chronic myelogenous leukemia progenitors remaining after imatinib treatment. Cancer Res 2007;67:1113-1120.
12. Kantarjian HM, Dixon D, Keating MJ, Talpaz M, Walters RS, McCredie KB, Freireich EJ: Characteristics of accelerated disease in chronic myelogenous leukemia. Cancer 1988;61:1441-1446. (Pubitemid 18076421)
13. Cross NC, Feng L, Chase A, Bungey J, Hughes TP, Goldman JM: Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood 1993;82:1929-1936. (Pubitemid 23278786)
14. + progenitors are resistant to apoptosis induced by a wide range of pro-apoptotic stimuli. Leukemia 2005;19:1034-1041. (Pubitemid 40862017)
15. Hui CH, Goh KY, White D, Branford S, Grigg A, Seymour JF, Kwan YL, Walsh S, Hoyt R, Trickett A, Rudzki B, Ma DD, To LB, Hughes TP: Successful peripheral blood stem cell mobilization with filgrastim in patients with chronic myeloid leukaemia achieving complete cytogenetic response with imatinib, without increasing disease burden as measured by quantitative real-time PCR. Leukemia 2003;17:821-828. (Pubitemid 36626306)
16. Drummond MW, Marin D, Clark RE, Byrne JL, Holyoake TL, Lennard A; United Kingdom Chronic Myeloid Leukaemia (UK CML) Working Party: Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. Br J Haematol 2003;123:479-483. (Pubitemid 37363491)
17. Marin D, Marktel S, Bua M, Szydlo RM, Franceschino A, Nathan I, Foot N, Crawley C, Na Nakorn T, Olavarria E, Lennard A, Neylon A, O'Brien SG, Goldman JM, Apperley JF: Prognostic factors for patients with chronic myeloid leukaemia in chronic phase treated with imatinib mesylate after failure of interferon α. Leukemia 2003;17:1448-1453. (Pubitemid 36986945)
18. Sneed TB, Kantarjian HM, Talpaz M, O'Brien S, Rios MB, Bekele BN, Zhou X, Resta D, Wierda W, Faderl S, Giles F, Cortes JE: The significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004;100:116-121. (Pubitemid 37553546)
19. Marin D, Marktel S, Foot N, Bua M, Goldman JM, Apperley JF: Granulocyte colony-stimulating factor reverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica 2003;88:227-229. (Pubitemid 37101505)
20. Heim D, Ebnother M, Meyer-Monard S, Tsakiris D, Linn M, Tichelli A, Gratwohl A: G-CSF for imatinibinduced neutropenia. Leukemia 2003;17:805-807.
21. Quintas-Cardama A, Kantarjian H, O'Brien S, Garcia-Manero G, Rios MB, Talpaz M, Cortes J: Granulocytecolony- stimulating factor (filgrastim) may overcome imatinib-induced neutropenia in patients with chronicphase chronic myelogenous leukemia. Cancer 2004;100:2592-2597. (Pubitemid 38715764)
22. Jorgensen HG, Copland M, Holyoake TL: Granulocyte-colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. Cancer 2005;103:210-211. (Pubitemid 39665476)
23. Fang B, Zheng C, Liao L, Han Q, Sun Z, Jiang X, Zhao RC: Identification of human chronic myelogenous leukemia progenitor cells with hemangioblastic characteristics. Blood 2005;105:2733-2740. (Pubitemid 40446263)